Dose-Response最新文献

筛选
英文 中文
Effects of Hawthorn Fruit Extract Drink in Chinese Patients With Mild Hypertension and/or Hyperlipidaemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. 山楂果提取物饮料对中国轻度高血压和/或高脂血症患者的影响:一项随机、双盲、安慰剂对照、交叉研究。
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-11-21 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241303136
Weiwei Zeng, Tanya T W Chu, Benny S P Fok, Walter K K Ho, Juliana C N Chan, Brian Tomlinson
{"title":"Effects of Hawthorn Fruit Extract Drink in Chinese Patients With Mild Hypertension and/or Hyperlipidaemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study.","authors":"Weiwei Zeng, Tanya T W Chu, Benny S P Fok, Walter K K Ho, Juliana C N Chan, Brian Tomlinson","doi":"10.1177/15593258241303136","DOIUrl":"10.1177/15593258241303136","url":null,"abstract":"<p><p><b>Objectives:</b> The purpose of this study was to examine the effect of hawthorn extract drink in mildly hypertensive and/or hyperlipidaemic Chinese patients. <b>Methods:</b> We performed a randomized double-blind placebo-controlled crossover study. Subjects who were randomly divided into 2 groups and asked to consume either hawthorn fruit extract drink or placebo with the same sugar content for 8-weeks with crossover to the alternative drink separated by a 4-weeks washout period. Adverse effects, lipid profile, fasting plasma glucose and blood pressure were recorded. <b>Results:</b> In 61 participants, body weight increased by mean (95% CI) 0.42 kg (-0.85, 1.69 kg) with the hawthorn drink and 0.94 kg (0.52, 1.36 kg) with placebo (<i>P</i> > .05). Systolic blood pressure and plasma total cholesterol increased significantly with both treatments and cholesterol sub-fractions showed no significant changes. Significant increases were seen in fasting plasma glucose with placebo. The increase in plasma glucose was reversed during the 4-week washout period. <b>Conclusions:</b> Although our results didn't show significant effects of hawthorn drink compared to placebo, there was a trend toward fewer adverse metabolic effects. A longer study with hawthorn fruit extract without additional calories would be useful to determine if beneficial effects occur in patients with mild hyperlipidaemia or hypertension.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241303136"},"PeriodicalIF":2.3,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Antiurolithiatic Effects of Moringa oleifera Lam. Leaves Extract: In-vitro, in-silico and in-vivo Approaches. 对油辣木叶提取物的抗尿石症作用的评估:体外、体内和硅学方法叶提取物:体外、硅内和体内方法。
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-11-12 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241301222
Hina Ali, Qaiser Jabeen, Ayesha Jamshed, Syeda Abida Ejaz, Maria Qadeer, Mariya Anwaar, Hafiz Muhammad Farhan Rasheed
{"title":"Evaluation of Antiurolithiatic Effects of <i>Moringa oleifera</i> Lam. Leaves Extract: <i>In-vitro</i>, <i>in-silico</i> and <i>in-vivo</i> Approaches.","authors":"Hina Ali, Qaiser Jabeen, Ayesha Jamshed, Syeda Abida Ejaz, Maria Qadeer, Mariya Anwaar, Hafiz Muhammad Farhan Rasheed","doi":"10.1177/15593258241301222","DOIUrl":"10.1177/15593258241301222","url":null,"abstract":"<p><p><b>Objective:</b> <i>Moringa oleifera</i> Lam. (Moringaceae), has traditionally been used for various renal diseases including urolithiasis. Considering the therapeutic and nutritional values, the present study was designed to investigate the antiurolithiatic potential of <i>M. oleifera</i> leaves through <i>in-vitro</i>, <i>in-silico</i> and <i>in-vivo</i> approaches. <b>Methods:</b> Methanolic aqueous extract of <i>M. oleifera</i>. leaves (MoL.Cr) was prepared and screened for phytoconstituents through FTIR and HPLC analysis, while antioxidant potential was determined by DPPH assay. Crystal nucleation, aggregation and growth assays were carried out to ascertain the <i>in-vitro</i> inhibitory effects of MoL.Cr. Molecular docking was performed to analyze the interactions between phytoconstituents and targeted proteins (Glycolate oxidase, Albumin and Tamm-Horsfall). Whereas, ethylene glycol-induced urolithiasis model (1% ammonium chloride +0.75% ethylene glycol) was used for <i>in-vivo</i> study. Presence of alkaloids, phenols, glycosides and flavonoids was confirmed by FTIR and HPLC analysis. <b>Results:</b> MoL.Cr significantly inhibited the CaOx crystal nucleation, aggregation as well as growth and normalized urinary and serum parameters. Histological studies showed that MoL.Cr significantly restored hyperoxaluria-induced irregular epithelial lining, interstitial inflammation and dilated proximal tubules. <b>Conclusions:</b> Thus, <i>M. oleifera</i> demonstrated marked stone inhibiting potential which can be due to its antioxidant, lowering of urinary concentration of stone forming constituents and anti-crystallization effects.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241301222"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter re: Overestimation of Adverse Effects of Low-Dose Low-Rate Ionizing Radiation: Cui Bono? 关于 "高估低剂量低速率电离辐射的不良影响 "的信函:Cui Bono?
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-11-12 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241301951
Sergei V Jargin
{"title":"Letter re: Overestimation of Adverse Effects of Low-Dose Low-Rate Ionizing Radiation: Cui Bono?","authors":"Sergei V Jargin","doi":"10.1177/15593258241301951","DOIUrl":"10.1177/15593258241301951","url":null,"abstract":"","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241301951"},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11558702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salidroside Pre-Treatment Inhibits Hypertensive Renal Injury and Fibrosis Through Inhibiting Wnt/β-Catenin Pathway. 水杨甙预处理通过抑制Wnt/β-Catenin通路抑制高血压肾损伤和纤维化
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-11-05 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241298045
Jie Zhu, Liang Li, Yuting Luan, Ziqing Zhang, Yi Wang, Zhenyu Xu
{"title":"Salidroside Pre-Treatment Inhibits Hypertensive Renal Injury and Fibrosis Through Inhibiting Wnt/β-Catenin Pathway.","authors":"Jie Zhu, Liang Li, Yuting Luan, Ziqing Zhang, Yi Wang, Zhenyu Xu","doi":"10.1177/15593258241298045","DOIUrl":"10.1177/15593258241298045","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to explore the protective effects and underlying mechanisms of salidroside (SAL) in angiotensin II (Ang II)-induced hypertensive renal injury and fibrosis, using in vivo and in vitro models.</p><p><strong>Methods: </strong>In this study, we generated Ang II-induced hypertensive renal injury and fibrosis in mice and the recombinant interferon-gamma (IFN-γ)-stimulated murine podocyte clone 5 (MPC5) model in vitro. Histological and oxidative stress analyses were performed to evaluate the renal injury.</p><p><strong>Results: </strong>SAL pre-treatment reduced systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial blood pressure (MAP), and attenuated serum creatinine (Scr), blood urea nitrogen (BUN), and serum cystatin C (Cys-C) levels in Ang II-infused mice (all, <i>P</i> < 0.001). SAL reduced renal fibrosis and related molecules expression, including Collagen I, Collagen III, and α-smooth muscle actin (α-SMA) (all, <i>P</i> < 0.001). SAL decreased the content of malondialdehyde (MDA) while increasing superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) in Ang II-treated mice (all, <i>P</i> < 0.001). In addition, SAL pre-treatment inhibited AT1R, Wnt1, Wnt3a, and β-catenin expressions (all, <i>P</i> < 0.001), both in vivo <i>and</i> in vitro.</p><p><strong>Conclusion: </strong>Our experimental data demonstrate that SAL pre-treatment protects against Ang II-induced hypertensive renal injury and fibrosis by suppressing the Wnt/β-catenin pathway in vivo and in vitro.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241298045"},"PeriodicalIF":2.3,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Random Threshold Model: A Low-Dose Radiation-Induced Risk Assessment Approach Considering Individual Susceptibility to Cancer. 随机阈值模型:考虑个人癌症易感性的低剂量辐射诱发风险评估方法。
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-11-03 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241298553
Takashi Yanagawa, Hisanori Fukunaga
{"title":"Random Threshold Model: A Low-Dose Radiation-Induced Risk Assessment Approach Considering Individual Susceptibility to Cancer.","authors":"Takashi Yanagawa, Hisanori Fukunaga","doi":"10.1177/15593258241298553","DOIUrl":"10.1177/15593258241298553","url":null,"abstract":"<p><p><b>Objectives:</b> The linear no-threshold (LNT) model, which has been used for radiation protection purposes, was developed based on the assumption that exposure to even a small amount of radiation may cause cancer. However, although it is known in carcinogenesis that there is variation in radiation sensitivity among individuals, the LNT model does not adequately consider radiosensitive subgroups. In this paper, we represent susceptibility to contract cancer by radiation exposure by means of the threshold of a dose-response function, introduce an assumption that the thresholds are random to represent the variation of the radiosensitivity among individuals in a susceptible subgroup. We propose a novel method, the random threshold (RT) model, for determining the safe dose limit for the subgroup to protect cancer-susceptible individuals from radiation exposure. <b>Conclusion:</b> The proposed method is illustrated by targeting <i>ATM</i> gene (a cancer-susceptible gene) mutation carriers as a radiosensitive subgroup. For cancer risk associated with low-dose radiation exposure, the contribution of radiosensitivity cannot be ignored, thus the RT model would be more suitable for risk protection for radiosensitive subgroups instead of the LNT model. We also notice that it could be widely applicable for risk protection of not only low-dose radiation but also environmental pollutants.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241298553"},"PeriodicalIF":2.3,"publicationDate":"2024-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Decrease of Prolylcarboxypeptidase Dose of Aqueous Humor is Involved in the Pathogenesis of Primary Open-Angle Glaucoma via Finetuning of the Local Ocular Renin-Angiotensin System. 通过微调局部眼部肾素-血管紧张素系统,降低水液中的前羧肽酶剂量参与原发性开角型青光眼的发病机制
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-10-29 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241298062
Jing Ren, Yuanyuan Xiao, Di Wang, Huiling Cui, Rumeng Zhao, Zilu Guo, Yuhao Wang, Shichao Zhu, Bo Tang, Jing Wang, Gang Wang, Huaying Wang, Xinyuan Hu, Rick F Thorne, Shichao Duan, Haijun Li
{"title":"Decrease of Prolylcarboxypeptidase Dose of Aqueous Humor is Involved in the Pathogenesis of Primary Open-Angle Glaucoma via Finetuning of the Local Ocular Renin-Angiotensin System.","authors":"Jing Ren, Yuanyuan Xiao, Di Wang, Huiling Cui, Rumeng Zhao, Zilu Guo, Yuhao Wang, Shichao Zhu, Bo Tang, Jing Wang, Gang Wang, Huaying Wang, Xinyuan Hu, Rick F Thorne, Shichao Duan, Haijun Li","doi":"10.1177/15593258241298062","DOIUrl":"10.1177/15593258241298062","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we investigated the cause of the AngII dose elevation in aqueous humor of primary open-angle glaucoma (POAG) patients.</p><p><strong>Methods: </strong>Enzyme-linked immunosorbent assay (ELISA), western blotting were used to detect concentration of Angiotensin Converting Enzyme 2 (ACE2) and Prolylcarboxypeptidase (PRCP). AngII and AngII + Recombinant PRCP were injected into anterior chamber of mouse eye. Mouse Intraocular pressure (IOP) was measured every week, mouse eye sections were conducted Hematoxylin-and-Eosin (H&E) staining, Masson' staining and Immunofluorescence staining. Western blotting and Immunofluorescence staining assays to detected fibrosis of trabecular meshwork cells. Mass spectrometry was used to identify proteins of aqueous humor.</p><p><strong>Results: </strong>PRCP dose are decreased in aqueous humor of POAG patients. There is a negative correlation between PRCP and AngII levels in aqueous humor and between PRCP levels and the IOP. PRCP treatment reverses fibrosis of trabecular meshwork (TM) and prevents IOP elevation induced by AngII. Exogenous PRCP rescues fibrosis induced by AngII in HTMCs. Proteome profiling detected 502 differentially expressed proteins.</p><p><strong>Conclusion: </strong>Our study found PRCP dose was decreased in POAG patients' aqueous humor, and it might cause high level of AngII. Restoration of PRCP rescued fibrosis of TM cells and ameliorated IOP in AngII treatment mouse.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241298062"},"PeriodicalIF":2.3,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paeoniflorin Inhibits Atrial Fibrosis and Atrial Fibrillation in Angiotensin II-Infused Mice Through the PI3K-Akt Pathway. 芍药苷通过 PI3K-Akt 通路抑制血管紧张素 II 注入小鼠的心房纤维化和心房颤动
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-10-25 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241277919
Yaqiong Ji, Zhongping Ning
{"title":"Paeoniflorin Inhibits Atrial Fibrosis and Atrial Fibrillation in Angiotensin II-Infused Mice Through the PI3K-Akt Pathway.","authors":"Yaqiong Ji, Zhongping Ning","doi":"10.1177/15593258241277919","DOIUrl":"10.1177/15593258241277919","url":null,"abstract":"<p><p><b>Objective:</b> The investigation aimed to analyze the effect of Paeoniflorin (PF) on the initiation of atrial fibrosis and atrial fibrillation (AF) induced by angiotensin II (Ang II) and explore its associated underlying mechanism. <b>Introduction:</b> PF has anti-inflammatory, immunomodulatory, antioxidant, hepatoprotective, and hypolipidemic properties. However, the protective effect of PF against atrial fibrosis and AF remains unclear. <b>Methods:</b> Male C57BL/6 mice aged 8-10 weeks, with 40 individuals, were subjected to subcutaneous infusion of either saline or Ang II at a dosage of 2.0 mg/kg/day. Furthermore, PF at a dosage of 100 mg/kg/day was administered through gavage once daily for 28 days. Morphological, histological, and biochemical examinations were undertaken. AF was elicited through in vivo transesophageal burst pacing. <b>Results:</b> PF treatment significantly improved AF in Ang II-infused mice. In addition, PF attenuated cardiac hypertrophy, atrial fibrotic area, atrial apoptosis and oxidative stress in Ang II-induced mice. The effect of PF on the PI3K-Akt pathway reduced the expression of phosphoinositide 3-kinase (p-PI3K) and Phosphorylated Akt (p-Akt) in Ang II-induced mice. <b>Conclusion:</b> PF may, therefore, avert Ang II-induced atrial fibrosis and AF by inhibiting the PI3K-Akt pathway.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241277919"},"PeriodicalIF":2.3,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11514121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retraction. 撤回。
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-10-18 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241282445
{"title":"Retraction.","authors":"","doi":"10.1177/15593258241282445","DOIUrl":"https://doi.org/10.1177/15593258241282445","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.1177/1559325820913786.][This retracts the article DOI: 10.1177/1559325820936124.][This retracts the article DOI: 10.1177/1559325820928687.][This retracts the article DOI: 10.1177/1559325820950061.][This retracts the article DOI: 10.1177/1559325820918052.][This retracts the article DOI: 10.1177/1559325820907016.][This retracts the article DOI: 10.1177/1559325820918450.][This retracts the article DOI: 10.1177/1559325820907536.][This retracts the article DOI: 10.1177/1559325820926764.][This retracts the article DOI: 10.1177/1559325820946194.].</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241282445"},"PeriodicalIF":2.3,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study. 雷莫司琼 3.0 μg/mL 与地塞米松(0.05、0.1、0.2 mg/mL)在输液中的组合:理化稳定性研究。
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-10-14 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241293220
Baoxia Fang, Lijun Zhao, Shirong Yu, Fuchao Chen
{"title":"Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study.","authors":"Baoxia Fang, Lijun Zhao, Shirong Yu, Fuchao Chen","doi":"10.1177/15593258241293220","DOIUrl":"https://doi.org/10.1177/15593258241293220","url":null,"abstract":"<p><strong>Background: </strong>Dexamethasone in conjunction with type 3 serotonin receptor antagonists are being used to the prevention and treatment of chemotherapy-induced nausea and vomiting and postoperative nausea and vomiting in clinic. The present study aimed to investigates the stability of ramosetron with dexamethasone in infusions, with the goal of enhancing the safety and clinical applicability of their combined use.</p><p><strong>Methods: </strong>Ramosetron hydrochloride (3.0 μg/mL) combining with dexamethasone (0.05, 0.1, 0.2 mg/mL) were prepared with 0.9% sodium chloride injection and then packaged in polyolefin bags or glass bottles. The stability were investigated kept in the dark at refrigeration for 14 days and at room temperature for 48 h.</p><p><strong>Results: </strong>The concentration of both drugs maintained at least 97% in the various solutions for both storage conditions with light protection. In the light exposure conditions, as the extension of storage time, the concentration of both drugs had declined. All antiemetic mixture solutions remained clear and no changes in color, turbidity, precipitation, and the pH remained stable. The insoluble particles were in line with Chinese Pharmacopoeia.</p><p><strong>Conclusion: </strong>Our findings suggest that combinations of ramosetron hydrochloride with dexamethasone sodium phosphate in 0.9% sodium chloride injection remain stable for 14 days at 4°C and 48 h at 25°C when protected from light.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241293220"},"PeriodicalIF":2.3,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11481085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuroprotective Potential of Eugenol in Polyglutamine-Mediated Neurodegenerative Disease Using Transgenic Drosophila Model. 利用转基因果蝇模型研究丁香酚对多谷氨酰胺介导的神经退行性疾病的神经保护潜力
IF 2.3 4区 医学
Dose-Response Pub Date : 2024-10-13 eCollection Date: 2024-10-01 DOI: 10.1177/15593258241291652
Anjalika Chongtham, Namita Agrawal
{"title":"Neuroprotective Potential of Eugenol in Polyglutamine-Mediated Neurodegenerative Disease Using Transgenic <i>Drosophila</i> Model.","authors":"Anjalika Chongtham, Namita Agrawal","doi":"10.1177/15593258241291652","DOIUrl":"https://doi.org/10.1177/15593258241291652","url":null,"abstract":"<p><p>Polyglutamine (PolyQ) diseases including Huntington's disease are devastating neurodegenerative disorders characterized by progressive neuronal loss and motor dysfunction. PolyQ pathology involves multiple cellular events and phytochemicals with multi-target mechanisms hold promise to treat these diseases with least side effects. One such promising phytochemical is Eugenol, which possesses antioxidant and anti-inflammatory properties, potentially targeting disrupted cellular pathways in PolyQ diseases. The present study investigated the effects of Eugenol on neurodegeneration and motor dysfunction in transgenic <i>Drosophila</i> models of PolyQ diseases. In this study, the robust pseudopupil assay was performed to analyze adult photoreceptor neuron degeneration, a marker of widespread degenerative events. Furthermore, the well-established crawling and climbing assays were conducted to evaluate progressive motor dysfunction in the PolyQ larvae and flies. This study found that Eugenol administration at disease onset or after progression reduced PolyQ disease phenotypes, particularly, neurodegeneration and motor dysfunction in a dose-dependent manner and with no side effects. Thus, this study suggests that Eugenol could be a viable candidate for developing treatments for PolyQ diseases, offering a multi-target approach with the potential for minimal or no side effects compared to conventional therapies.</p>","PeriodicalId":11285,"journal":{"name":"Dose-Response","volume":"22 4","pages":"15593258241291652"},"PeriodicalIF":2.3,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11475233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信